Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients

Nephrology Dialysis Transplantation

Volumn 19, Issue 5, 2004, Pages 1224-1230

  Brunkhorst, Reinhard ^a,g   Bommer, Jürgen ^b   Braun, Johann ^c   Haag Weber, Marianne ^d   Gill, Caroline ^e   Wagner, Jürgen ^f   Wagener, Thomas ^f  

^a Klinikum Hannover Oststadt   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KfH Center for Dialysis   (Germany)

^d KfH Center for Dialysis   (Germany)

^e AMGEN LTD   (United Kingdom)

^f Amgen Research GmbH   (Germany)

^g Krankenhaus Oststadt   (Germany)

Author keywords

Darbepoetin alfa; Dialysis; Haemoglobin; Renal anaemia; Route of administration; Safety

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPOIESIS; FEMALE; HEART ARREST; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INJECTION PAIN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANEMIA; CONTINENTAL POPULATION GROUPS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 2442702016     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh106     Document Type: Article

References (21)

1. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395
2. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 [Suppl 3]: 3-13
3. Coyne D, Ling BN, Toto R, McDermott-Vitak AD, Trotman ML, Jackson L. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO). J Am Soc Nephrol 2000; 11: A1380
4. Graf H, Lacombe J-L, Braun J, Gomes da Costa AA and the European/Australian NESP 980140/194 Study Group. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients. J Am Soc Nephrol 2000; 11: A1317
5. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-118
6. Vanrenterghem Y, Jadoul M, Foret M, Walker R and the European/Australian NESP 2000-0144 Study Group. Novel erythropoiesis stimulating protein (NESP) administered once every 3 weeks by the intravenous or subcutaneous route maintains hemoglobin (Hb) in dialysis patients. J Am Soc Nephrol 2001; 365A: A1878
7. Vanrenterghem Y, Bárány P, Mann JFE et al. Randomized trial of darbepoetin alfa for treatment of renal anaemia at a reduced dosing frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-2175
8. Locatelli F, Canaud B, Giacardy, F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-369
9. Braun J on behalf of the 20000144 Study Group. Darbepoetin alfa administered once every 4 weeks maintains Hb levels in patients with chronic kidney disease (CKD) receiving dialysis [abstract M317]. Nephrol Dial Transplant 2002; 17 [Suppl 12]: 136
10. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747
11. Suranyi MG, Lindberg JS, Navarro J, Elias J, Brenner RM, Walker R. Treatment of anaemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003; 23: 106-111
12. Walczyk M, Agarwal A, Ling B et al. Aranesp® (darbepoetin alfa) administered once monthly maintains hemoglobin levels in patients with chronic kidney disease (CKD). National Kidney Foundation Clinical Nephrology Meeting, Spring 2003. Dallas, April 2-6, 2003
13. Canaud B. Darbepoetin alfa dose requirements for i.v. and s.c. administration are equivalent in anaemic dialysis patients [abstract M319]. Nephrol Dial Transplant 2002; 17 [Suppl 12]: 137
14. Hörl WH. IV darbepoetin alfa is more effective than IV rHuEPO in maintaining target Hb concentrations in patients with renal anaemia [abstract O77]. Nephrol Dial Transplant 2002; 17 [Suppl 12]
15. Aljama P, Bommer J, Canaud B et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001; 16 [Suppl 3]: 22-28
16. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89
17. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 5]: 1-50
18. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30 [Suppl 3]: S192-S240
19. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B, on behalf of the Swedish Study Group. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomised controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014-2019
20. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL, on behalf of the Study Group. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002; 40: 119-125
21. Lindberg J. Darbepoetin alfa: a ew therapy for the management of anaemia associated with chronic kidney disease. Expert Opin Biol Ther 2002; 2: 977-984.